OFLOXINE

A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

For the treatment of infections (respiratory tract, kidney, skin, soft tissue, UTI), urethral and cervical gonorrhoea.

Ofloxacin is a quinolone/fluoroquinolone antibiotic.

Ofloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two.

Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian.

Ofloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria.

gyrase subunit A (Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)) Inhibitor DNA topoisomerase 4 subunit A (Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)) Inhibitor DNA topoisomerase 2-alpha Inhibitor.

Bioavailability of ofloxacin in the tablet formulation is approximately 98%.

Ofloxacin is mainly eliminated by renal excretion, where between 65% and 80% of an administered oral dose of ofloxacin is excreted unchanged via urine within 48 hours of dosing.

About 4-8% of an ofloxacin dose is excreted in the feces and the drug is minimally subject to biliary excretion.

Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.